GI
KYMR icon

GAMMA Investing’s Kymera Therapeutics KYMR Stock Holding History

GAMMA Investing’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.1K Buy
454
+98
+28% +$8.42K ﹤0.01% 2270
2026
Q1 		$29.7K Buy
356
+58
+19% +$4.59K ﹤0.01% 2505
2025
Q4 		$23.2K Buy
298
+127
+74% +$8.58K ﹤0.01% 2533
2025
Q3 		$9.68K Sell
171
-15
-8% -$677 ﹤0.01% 2890
2025
Q2 		$8.12K Sell
186
-58
-24% -$2K ﹤0.01% 2910
2025
Q1 		$6.68K Buy
244
+75
+44% +$2.73K ﹤0.01% 2946
2024
Q4 		$6.8K Sell
169
-13
-7% -$587 ﹤0.01% 2781
2024
Q3 		$8.61K Buy
182
+60
+49% +$2.65K ﹤0.01% 2519
2024
Q2 		$3.64K Buy
122
+44
+56% +$1.52K ﹤0.01% 2679
2024
Q1 		$3.14K Buy
78
+67
+609% +$2.4K ﹤0.01% 2588
2023
Q4 		$361 Buy
+11
New +$197 ﹤0.01% 3023

Other funds holding KYMR

PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
KMWM
Keudell/Morrison Wealth Management Salem, Oregon $529M AUM
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
DWM
Drive Wealth Management Lehi, Utah $561M AUM 33.14% 1-Year Est. Return
EFMH
E Fund Management (HK) Central, Hong Kong $302M AUM 64.42% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

GAMMA Investing's KYMR Position: Q2 2026 in Review

GAMMA Investing increased its Kymera Therapeutics (KYMR) stake by 28% in Q2 2026, buying an estimated $8.42K and bringing the position to 454 shares worth $52.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2270.

GAMMA Investing first reported a position in KYMR in Q4 2023 and has held it in 11 quarters since. 19 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • GAMMA Investing held 454 shares of Kymera Therapeutics worth $52.1K as of Q2 2026.
  • GAMMA Investing bought 98 Kymera Therapeutics shares in Q2 2026, an estimated $8.42K.
  • Kymera Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #2270 holding.
  • GAMMA Investing first reported a position in Kymera Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 19 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.